(0.05%) 5 519.50 points
(0.12%) 39 890 points
(0.12%) 19 775 points
(-0.02%) $81.61
(0.43%) $2.82
(-0.21%) $2 339.50
(0.25%) $29.60
(0.50%) $1 006.80
(0.06%) $0.932
(-0.11%) $10.52
(-0.01%) $0.788
(-0.85%) $87.25
0.00% $ 44.15
Live Chart Being Loaded With Signals
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders...
Stats | |
---|---|
Dzisiejszy wolumen | 1.24M |
Średni wolumen | 566 901 |
Kapitalizacja rynkowa | 915.89M |
EPS | $-1.950 ( Q3 | 2022-11-08 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-6.63 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.932 (2.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-02 | Chiswell David | Sell | 56 278 | Common Stock |
2023-03-02 | Chiswell David | Sell | 8 000 | Stock Option (Right to Buy) |
2023-03-02 | Chiswell David | Sell | 8 000 | Stock Option (Right to Buy) |
2023-03-02 | Chiswell David | Sell | 8 000 | Stock Option (Right to Buy) |
2023-03-02 | Chiswell David | Sell | 5 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-51.11 |
Last 100 transactions |
Buy: 1 059 000 | Sell: 2 762 067 |
Wolumen Korelacja
Albireo Pharma Inc Korelacja
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Albireo Pharma Inc Korelacja - Waluta/Towar
Albireo Pharma Inc Finanse
Annual | 2021 |
Przychody: | $40.58M |
Zysk brutto: | $39.22M (96.66 %) |
EPS: | $-1.770 |
FY | 2021 |
Przychody: | $40.58M |
Zysk brutto: | $39.22M (96.66 %) |
EPS: | $-1.770 |
FY | 2020 |
Przychody: | $8.31M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-6.73 |
FY | 2019 |
Przychody: | $9.64M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-5.04 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Albireo Pharma Inc
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej